Michael Makris/LinkedIn
Feb 28, 2026, 16:16
Michael Makris: Lower Doses of Hemlibra May Still Be Effective
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn about his recent commentary, adding:
”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.
You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”
Title: Is all the approved emicizumab dose essential?
Authors: Michael Makris
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 15, 2026, 19:41Looking Beyond Platelet Counts to Quality of Life in ITP – American Society of Hematology
-
Oct 15, 2026, 19:32Markus Gregorio Barbosa: Hepatic VPS35 and Cholesterol Homeostasis
-
Oct 15, 2026, 19:18Emerging Novel Therapies for Hereditary Hemorrhagic Telangiectasia – The Lancet Haematology
-
Oct 15, 2026, 19:04Umberto Pensato: EVT Treatment Effects Across Perfusion Profiles in MeVO Stroke
-
Oct 15, 2026, 18:26Chanakya Nayudu: Presenting My Research at ISTH Congress 2026 in Paris
-
Oct 15, 2026, 18:09Maha Othman: Students Lead World Thrombosis Day 2026 Awareness Events
-
Oct 15, 2026, 17:52Jill de Mol։ Rapamycin Modulates Immune Responses in Aged Atherosclerosis
-
Oct 15, 2026, 17:41Victor Aboyans։ Think About Lipids in VTE
-
Oct 15, 2026, 17:08Babu Mia։ Targeting PPM1D to Eliminate Malignant Stem Cells in Myeloproliferative Neoplasms